Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis

Autor: Tingwang Jiang, Yulan Gu, Chuandan Wan, Zhixiang Zhuang, Yanhong Cui, Jiaming Qiu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Viral Diseases
Uterine Cervical Neoplasms
Cervical Cancer
Pathology and Laboratory Medicine
Likelihood ratios in diagnostic testing
Biochemistry
Database and Informatics Methods
0302 clinical medicine
Mathematical and Statistical Techniques
Medicine and Health Sciences
Medicine
Database Searching
Prospective cohort study
Cervical cancer
Multidisciplinary
Statistics
Metaanalysis
Infectious Diseases
Medical Microbiology
030220 oncology & carcinogenesis
Viral Pathogens
Viruses
Physical Sciences
Biomarker (medicine)
Female
Pathogens
Cell-Free Nucleic Acids
Research Article
medicine.medical_specialty
Human Papillomavirus Infection
Papillomaviruses
Urology
Science
Sexually Transmitted Diseases
Research and Analysis Methods
Sensitivity and Specificity
Microbiology
03 medical and health sciences
Diagnostic Medicine
Internal medicine
Biomarkers
Tumor
Cancer Detection and Diagnosis
Humans
Liquid biopsy
Statistical Methods
Microbial Pathogens
Tumor marker
Circulating tumor DNA
Biology and life sciences
business.industry
Genitourinary Infections
Papillomavirus Infections
Organisms
Cancer
Cancers and Neoplasms
Human Papillomavirus
medicine.disease
030104 developmental biology
ROC Curve
Diagnostic odds ratio
business
DNA viruses
Gynecological Tumors
Mathematics
Biomarkers
Zdroj: PLoS ONE, Vol 15, Iss 2, p e0224001 (2020)
PLoS ONE
ISSN: 1932-6203
Popis: The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker, especially circulating HPV DNA (HPV cDNA) in cervical cancer remains unclear. Here, we performed a meta-analysis to evaluate the applications of HPV cDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of HPV cDNA in cervical cancer were pooled and investigated. Fifteen studies comprising 684 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.27 (95% confidence interval [CI], 0.24-0.30) and 0.94(95% CI, 0.92-0.96), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 6.85 (95% CI, 3.09-15.21) and 0.60 (95% CI, 0.46-0.78), respectively. The diagnostic odds ratio was 15.25 (95% CI, 5.42-42.94), and the area under the summary receiver operating characteristic curve was 0.94 (95% CI, 0.89-0.99). There was no significant publication bias observed. In the included studies, HPV cDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our meta-analysis suggested that detection of HPV cDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring.
Databáze: OpenAIRE
Externí odkaz: